Lenvatinib is a multi-kinase inhibitor primarily used in the treatment of certain types of cancer. It is approved for use in advanced or metastatic differentiated thyroid cancer that is resistant to radioactive iodine. It is also utilized in combination with everolimus for the treatment of advanced renal cell carcinoma following one prior anti-angiogenic therapy. Additionally, Lenvatinib is indicated as a single agent for unresectable hepatocellular carcinoma, providing a systemic treatment option for patients with this challenging form of liver cancer. Furthermore, in combination with pembrolizumab, it is approved for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Its mechanism involves inhibiting multiple kinase enzymes, including vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT, which helps in slowing the progression of these cancers by targeting the blood vessels that supply tumors and the tumor cells themselves. Common side effects include hypertension, fatigue, diarrhea, and other gastrointestinal issues.